Clinical Trials

Viral infections

Displaying 2 studies

  • Use Of Tecovirimat (TPOXX®) For Treatment Of Human Orthopoxvirus Infections Albert Lea, MN; Scottsdale/Phoenix, AZ; Austin, MN; Cannon Falls, MN; Eau Claire, WI; Jacksonville, FL; La Crosse, WI; Lake City, MN; Mankato, MN; Owatonna, MN; Rochester, MN; Red Wing, MN

    The purpose of this expanded access IND treatment program is to provide tecovirimat for primary or early empiric treatment of confirmed or suspected (based on clinical signs and symptoms with known exposure while laboratory confirmation may be pending) non-variola orthopoxvirus infections (e.g., vaccinia, monkeypox, cowpox or other human virus infection identified as an orthopoxvirus) and secondary treatment of complications from replication competent vaccinia vaccine in adults and children.

  • Phase III DAS181 Lower Tract PIV Infection In Immunocompromised Subjects (Substudy: DAS181 For COVID-19): RCT Study Rochester, MN

    The purpose of this study is to evaluate the effectiveness of an investigational drug called DAS181 compared to placebo in the treatment of PIV. 

.

Mayo Clinic Footer